AHA Survey on 340B Rebate Model Closes Jan. 10
What’s happening: The American Hospital Association (AHA) is asking hospitals to complete a survey by Jan. 10 to help it understand how a 340B rebate model would impact 340B member hospitals.
What else to know: Completing this 10-question survey will help AHA understand the financial, operational, and patient impacts that a rebate model — such as the one Johnson & Johnson sought to implement this year — would have on your hospital or health system.
Urge Congress to Support Patient Care in Year-End Legislation
What’s happening: CHA issued an alert asking members to urge their congressional representatives to support hospital priority issues in year-end legislation.
What else to know: Outreach is needed by Dec. 20 when Congress will wrap up the session.
CHA Outlines Year-End Federal Legislative Health Care Priorities
What’s happening: In a Nov. 18 letter to the California congressional delegation, CHA outlined legislative priorities for the remainder of the 118th Congress — which must act by Dec. 20 to fund the federal government.
What else to know: It is likely that some health care extensions and policies could be a part of Congress’ funding package.
Johnson & Johnson Halts Proposed 340B Rebate Model
What’s happening: Johnson & Johnson will stop its plan that would have required hospitals participating in the 340B drug discount program to purchase Stelara and Xarelto at full price and apply for a rebate instead of receiving full discounts upfront.
What else to know: The Health Resources and Services Administration (HRSA) notified J&J it would be kicked out of the 340B Drug Pricing Program if it did not halt implementation.
Ask Reps. to Sign Letter Opposing 340B Program Changes
What’s happening: A bipartisan group of U.S. representatives is leading a letter to U.S. Health and Human Services (HHS) Secretary Xavier Becerra about efforts by Johnson & Johnson (J&J) to undermine the 340B Drug Discount Program.
What else to know: Hospital leaders should call or email their U.S. representative and urge them to sign on to the letter by Sept. 27.
Hospitals Should Encourage Reps. to Sign Letter Opposing 340B Program Changes
What’s happening: A bipartisan group of U.S. representatives is leading a letter to U.S. Health and Human Services (HHS) Secretary Xavier Becerra about efforts by Johnson & Johnson (J&J) to undermine the 340B Drug Discount Program.
What else to know: The deadline for signatures is expected to be extended but since the House could go out of session at any time, it’s urgent to ask your representative to sign now.
CHA Urges Hospitals to Invite Members of Congress to Visit
What’s happening: CHA issued an alert encouraging members to meet with their representatives to discuss key issues like the 340B Drug Pricing Program, financial instability, prior authorization, rural health care, disproportionate share hospital payment cuts, and site-neutral payment policies.
What else to know: Members of Congress will be back in their districts for the entire month of October. These visits will not only strengthen relationships, but also help educate and inform your representative ahead of critical health care policy votes in December.
Annual 340B Recertification Period for Hospitals Approaching
What’s happening: The Health Resources and Services Administration’s (HRSA) annual 340B Drug Pricing Program recertification window for hospitals will be open from Aug. 12 to Sept. 9.
What else to know: Recertification is required for all hospitals currently participating in the 340B program. Hospitals that do not complete the recertification process will be removed from the 340B program.